FALLETTA, PAOLA
FALLETTA, PAOLA
Facoltà di Medicina e Chirurgia
A phosphatidylinositol 3-Kinase-Pax3 axis regulates Brn-2 expression in melanoma
2012-01-01 Bonvin, E.; Falletta, P.; Shaw, H.; Delmas, V.; Goding, C. R.
BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma
2019-01-01 Herbert, K.; Binet, R.; Lambert, J. -P.; Louphrasitthiphol, P.; Kalkavan, H.; Sesma-Sanz, L.; Robles-Espinoza, C. D.; Sarkar, S.; Suer, E.; Andrews, S.; Chauhan, J.; Roberts, N. D.; Middleton, M. R.; Gingras, A. -C.; Masson, J. -Y.; Larue, L.; Falletta, P.; Goding, C. R.
Chromatin organization drives the search mechanism of nuclear factors
2023-01-01 Mazzocca, Matteo; Loffreda, Alessia; Colombo, Emanuele; Fillot, Tom; Gnani, Daniela; Falletta, Paola; Monteleone, Emanuele; Capozi, Serena; Bertrand, Edouard; Legube, Gaelle; Lavagnino, Zeno; Tacchetti, Carlo; Mazza, Davide
Connecting Metabolic Rewiring With Phenotype Switching in Melanoma
2022-01-01 Falletta, Paola; Goding, Colin R.; Vivas-García, Yurena
Establishment of a fluorescent reporter of RNA-polymerase II activity to identify dormant cells
2021-01-01 Freter, R.; Falletta, P.; Omrani, O.; Rasa, M.; Herbert, K.; Annunziata, F.; Minetti, A.; Krepelova, A.; Adam, L.; Kappel, S.; Rudiger, T.; Wang, Z. -Q.; Goding, C. R.; Neri, F.
Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity
2020-01-01 Vivas-Garcia, Y.; Falletta, P.; Liebing, J.; Louphrasitthiphol, P.; Feng, Y.; Chauhan, J.; Scott, D. A.; Glodde, N.; Chocarro-Calvo, A.; Bonham, S.; Osterman, A. L.; Fischer, R.; Ronai, Z.; Garcia-Jimenez, C.; Holzel, M.; Goding, C. R.
Melanosome-autonomous regulation of size and number: the OA1 receptor sustains PMEL expression.
2014-01-01 Falletta, P; Bagnato, P; Bono, M; Monticone, M; Schiaffino, Mv; Bennett, Dc; Goding, Cr; Tacchetti, Carlo; Valetti, C.
MITF controls the TCA cycle to modulate the melanoma hypoxia response
2019-01-01 Louphrasitthiphol, P.; Ledaki, I.; Chauhan, J.; Falletta, P.; Siddaway, R.; Buffa, F. M.; Mole, D. R.; Soga, T.; Goding, C. R.
Neratinib is a TFEB and TFE3 activator that potentiates autophagy and unbalances energy metabolism in ERBB2+ breast cancer cells
2023-01-01 Bellese, G.; Tagliatti, E.; Gagliani, M. C.; Santamaria, S.; Arnaldi, P.; Falletta, P.; Rusmini, P.; Matteoli, M.; Castagnola, P.; Cortese, K.
Organelle-autonomous regulation of size and number: OA1 receptor sustains Pmel17 expression
2011-01-01 Falletta, P.; Bono, M.; Bagnato, P.; Monticone, M.; Bennett, D. C.; Schiaffino, M. V.; Goding, C. R.; Tacchetti, Carlo; Valetti, C.
The two faces of the Integrated Stress Response in cancer progression and therapeutic strategies
2021-01-01 Licari, E.; Sanchez-del-Campo, L.; Falletta, P.
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma
2017-01-01 Falletta, P.; Sanchez-del-Campo, L.; Chauhan, J.; Effern, M.; Kenyon, A.; Kershaw, C. J.; Siddaway, R.; Lisle, R.; Freter, R.; Daniels, M. J.; Lu, X.; Tüting, T.; Middleton, M.; Buffa, F. M.; Willis, A. E.; Pavitt, G.; Ronai, Z. A.; Sauka-Spengler, T.; Hölzel, M.; Goding, C. R.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A phosphatidylinositol 3-Kinase-Pax3 axis regulates Brn-2 expression in melanoma | 1-gen-2012 | Bonvin, E.; Falletta, P.; Shaw, H.; Delmas, V.; Goding, C. R. | |
BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma | 1-gen-2019 | Herbert, K.; Binet, R.; Lambert, J. -P.; Louphrasitthiphol, P.; Kalkavan, H.; Sesma-Sanz, L.; Robles-Espinoza, C. D.; Sarkar, S.; Suer, E.; Andrews, S.; Chauhan, J.; Roberts, N. D.; Middleton, M. R.; Gingras, A. -C.; Masson, J. -Y.; Larue, L.; Falletta, P.; Goding, C. R. | |
Chromatin organization drives the search mechanism of nuclear factors | 1-gen-2023 | Mazzocca, Matteo; Loffreda, Alessia; Colombo, Emanuele; Fillot, Tom; Gnani, Daniela; Falletta, Paola; Monteleone, Emanuele; Capozi, Serena; Bertrand, Edouard; Legube, Gaelle; Lavagnino, Zeno; Tacchetti, Carlo; Mazza, Davide | |
Connecting Metabolic Rewiring With Phenotype Switching in Melanoma | 1-gen-2022 | Falletta, Paola; Goding, Colin R.; Vivas-García, Yurena | |
Establishment of a fluorescent reporter of RNA-polymerase II activity to identify dormant cells | 1-gen-2021 | Freter, R.; Falletta, P.; Omrani, O.; Rasa, M.; Herbert, K.; Annunziata, F.; Minetti, A.; Krepelova, A.; Adam, L.; Kappel, S.; Rudiger, T.; Wang, Z. -Q.; Goding, C. R.; Neri, F. | |
Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity | 1-gen-2020 | Vivas-Garcia, Y.; Falletta, P.; Liebing, J.; Louphrasitthiphol, P.; Feng, Y.; Chauhan, J.; Scott, D. A.; Glodde, N.; Chocarro-Calvo, A.; Bonham, S.; Osterman, A. L.; Fischer, R.; Ronai, Z.; Garcia-Jimenez, C.; Holzel, M.; Goding, C. R. | |
Melanosome-autonomous regulation of size and number: the OA1 receptor sustains PMEL expression. | 1-gen-2014 | Falletta, P; Bagnato, P; Bono, M; Monticone, M; Schiaffino, Mv; Bennett, Dc; Goding, Cr; Tacchetti, Carlo; Valetti, C. | |
MITF controls the TCA cycle to modulate the melanoma hypoxia response | 1-gen-2019 | Louphrasitthiphol, P.; Ledaki, I.; Chauhan, J.; Falletta, P.; Siddaway, R.; Buffa, F. M.; Mole, D. R.; Soga, T.; Goding, C. R. | |
Neratinib is a TFEB and TFE3 activator that potentiates autophagy and unbalances energy metabolism in ERBB2+ breast cancer cells | 1-gen-2023 | Bellese, G.; Tagliatti, E.; Gagliani, M. C.; Santamaria, S.; Arnaldi, P.; Falletta, P.; Rusmini, P.; Matteoli, M.; Castagnola, P.; Cortese, K. | |
Organelle-autonomous regulation of size and number: OA1 receptor sustains Pmel17 expression | 1-gen-2011 | Falletta, P.; Bono, M.; Bagnato, P.; Monticone, M.; Bennett, D. C.; Schiaffino, M. V.; Goding, C. R.; Tacchetti, Carlo; Valetti, C. | |
The two faces of the Integrated Stress Response in cancer progression and therapeutic strategies | 1-gen-2021 | Licari, E.; Sanchez-del-Campo, L.; Falletta, P. | |
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma | 1-gen-2017 | Falletta, P.; Sanchez-del-Campo, L.; Chauhan, J.; Effern, M.; Kenyon, A.; Kershaw, C. J.; Siddaway, R.; Lisle, R.; Freter, R.; Daniels, M. J.; Lu, X.; Tüting, T.; Middleton, M.; Buffa, F. M.; Willis, A. E.; Pavitt, G.; Ronai, Z. A.; Sauka-Spengler, T.; Hölzel, M.; Goding, C. R. |